Stimulation of respiratory motor output and ventilation in a murine model of Pompe disease by ampakines

American Journal of Respiratory Cell and Molecular Biology

Volumn 53, Issue 3, 2015, Pages 326-335

  ElMallah, Mai K ^a,d   Pagliardini, Silvia ^c   Turner, Sara M ^b   Cerreta, Anthony J ^b   Falk, Darin J ^a,b   Byrne, Barry J ^a,b   Greer, John J ^c   Fuller, David D ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Ampakines; Medulla; Neuropathology; Pompe disease; Respiratory insufficiency

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPAKINE CX717; GLUTAMATE RECEPTOR; UNCLASSIFIED DRUG; CX717; ISOXAZOLE DERIVATIVE; RESPIRATORY TRACT AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTIFICIAL VENTILATION; BODY PLETHYSMOGRAPHY; BREATHING PATTERN; CONTROLLED STUDY; GLYCOGEN STORAGE DISEASE TYPE 2; HISTOPATHOLOGY; HYPOGLOSSAL NERVE; IMMUNOCHEMISTRY; MOTONEURON; MOUSE; NEUROPATHOLOGY; NONHUMAN; RESPIRATION CONTROL; RESPIRATORY MOTOR OUTPUT; RESPIRATORY NERVE CELL; RESPIRATORY TRACT PARAMETERS; TIDAL VOLUME; WILD TYPE; 129 MOUSE; ANIMAL; BRAIN STEM; BREATHING; DRUG EFFECTS; DRUG SCREENING; GLYCOGEN STORAGE DISEASE TYPE II; KNOCKOUT MOUSE; MOTOR ACTIVITY; PATHOLOGY; PATHOPHYSIOLOGY; PHRENIC NERVE;

ANIMALS; BRAIN STEM; DRUG EVALUATION, PRECLINICAL; GLYCOGEN STORAGE DISEASE TYPE II; ISOXAZOLES; MICE, 129 STRAIN; MICE, KNOCKOUT; MOTOR ACTIVITY; PHRENIC NERVE; RESPIRATION; RESPIRATORY SYSTEM AGENTS;

EID: 84941555592     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2014-0374OC     Document Type: Article

References (55)

1. DeRuisseau LR, Fuller DD, Qiu K, DeRuisseau KC, Donnelly WH Jr, Mah C, Reier PJ, Byrne BJ. Neural deficits contribute to respiratory insufficiency in Pompe disease. Proc Natl Acad Sci USA 2009;106:9419-9424.
2. Raben N, Plotz P, Byrne BJ. Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr Mol Med 2002;2:145-166.
3. Sidman RL, Taksir T, Fidler J, Zhao M, Dodge JC, Passini MA, Raben N, Thurberg BL, Cheng SH, Shihabuddin LS. Temporal neuropathologic and behavioral phenotype of 6neo/6neo Pompe disease mice. J Neuropathol Exp Neurol 2008;67:803-818.
4. Fuller DD, ElMallah MK, Smith BK, Corti M, Lawson LA, Falk DJ, Byrne BJ. The respiratory neuromuscular system in Pompe disease. Respir Physiol Neurobiol 2013;189:241-249.
5. Byrne BJ, Falk DJ, Pacak CA, Nayak S, Herzog RW, Elder ME, Collins SW, Conlon TJ, Clement N, Cleaver BD, et al. Pompe disease gene therapy. Hum Mol Genet 2011;20:R61-R68.
6. Fuller DD, ElMallah MK, Falk DJ, Lawson L, Martin D, Smith B, Byrne BJ. The importance of targeting the central nervous system (CNS) for treatment of respiratory insufficiency in Pompe disease. Orlando, FL: World Lysosomal Meeting; 2013.
7. Lee KZ, Qiu K, Sandhu MS, Elmallah MK, Falk DJ, Lane MA, Reier PJ, Byrne BJ, Fuller DD. Hypoglossal neuropathology and respiratory activity in Pompe mice. Front Physiol 2011;2:31.
8. Muller CW, Jones HN, O'Grady G, Suarez AH, Heller JH, Kishnani PS. Language and speech function in children with infantile Pompe disease. J Pediatr Neurol 2009;7:147-156.
9. van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, Herson S, Kishnani PS, Laforet P, Lake SL, et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 2010;362:1396-1406.
10. Raben N, Nagaraju K, Lee E, Kessler P, Byrne B, Lee L, LaMarca M, King C, Ward J, Sauer B, et al. Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J Biol Chem 1998;273:19086-19092.
11. Staubli U, Rogers G, Lynch G. Facilitation of glutamate receptors enhances memory. Proc Natl Acad Sci USA 1994;91:777-781.
12. Arai A, Kessler M, Xiao P, Ambros-Ingerson J, Rogers G, Lynch G. A centrally active drug that modulates AMPA receptor gated currents. Brain Res 1994;638:343-346.
13. Ren J, Poon BY, Tang Y, Funk GD, Greer JJ. Ampakines alleviate respiratory depression in rats. Am J Respir Crit Care Med 2006;174:1384-1391.
14. Oertel BG, Felden L, Tran PV, Bradshaw MH, Angst MS, Schmidt H, Johnson S, Greer JJ, Geisslinger G, Varney MA, et al. Selective antagonism of opioid-induced ventilatory depression by an ampakine molecule in humans without loss of opioid analgesia. Clin Pharmacol Ther 2010;87:204-211.
15. Ren J, Ding X, Greer JJ. Respiratory depression in rats induced by alcohol and barbiturate and alleviation by ampakine CX717. J Appl Physiol 2012;113:1004-1011.
16. Ren J, Lenal F, Yang M, Ding X, Greer JJ. Coadministration of the AMPAKINE CX717 with propofol reduces respiratory depression and fatal apneas. Anesthesiology 2013;118:1437-1445.
17. Ren J, Ding X, Funk GD, Greer JJ. Ampakine CX717 protects against fentanyl-induced respiratory depression and lethal apnea in rats. Anesthesiology 2009;110:1364-1370.
18. Elmallah MK, Falk DJ, Nayak S, Federico RA, Sandhu MS, Poirier A, Byrne BJ, Fuller DD. Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in Pompe mice. Mol Ther 2014;22:702-712.
19. Falk DJ, Mah CS, Soustek MS, Lee KZ, Elmallah MK, Cloutier DA, Fuller DD, Byrne BJ. Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease. Mol Ther 2013;21:1661-1667.
20. Lorier AR, Funk GD, Greer JJ. Opiate-induced suppression of rat hypoglossal motoneuron activity and its reversal by ampakine therapy. PLoS One 2010;5:e8766.
21. Lee KZ, Reier PJ, Fuller DD. Phrenic motoneuron discharge patterns during hypoxia-induced short-term potentiation in rats. J Neurophysiol 2009;102:2184-2193.
22. Pagliardini S, Ren J, Greer JJ. Ontogeny of the pre-Bötzinger complex in perinatal rats. J Neurosci 2003;23:9575-9584.
23. Pagliardini S, Ren J, Gray PA, Vandunk C, Gross M, Goulding M, Greer JJ. Central respiratory rhythmogenesis is abnormal in Lbx1-deficient mice. J Neurosci 2008;28:11030-11041.
24. Smith JC, Ellenberger HH, Ballanyi K, Richter DW, Feldman JL. Pre-Bötzinger complex: a brainstem region that may generate respiratory rhythm in mammals. Science 1991;254:726-729.
25. Gray PA, Rekling JC, Bocchiaro CM, Feldman JL. Modulation of respiratory frequency by peptidergic input to rhythmogenic neurons in the preBötzinger complex. Science 1999;286:1566-1568.
26. Stornetta RL, Rosin DL, Wang H, Sevigny CP, Weston MC, Guyenet PG. A group of glutamatergic interneurons expressing high levels of both neurokinin-1 receptors and somatostatin identifies the region of the pre-Bötzinger complex. J Comp Neurol 2003;455:499-512.
27. Pagliardini S, Adachi T, Ren J, Funk GD, Greer JJ. Fluorescent tagging of rhythmically active respiratory neurons within the pre-Bötzinger complex of rat medullary slice preparations. J Neurosci 2005;25:2591-2596.
28. Burghaus L, Liu W, Neuen-Jacob E, Gempel K, Haupt WF. Glycogenesis type II (M. Pompe): selective failure of the respiratory musculature - a rare first symptom [in German]. Nervenarzt 2006;77:181-182, 185-186.
29. Mellies U, Lofaso F. Pompe disease: a neuromuscular disease with respiratory muscle involvement. Respir Med 2009;103:477-484.
30. Mellies U, Stehling F, Dohna-Schwake C, Ragette R, Teschler H, Voit T. Respiratory failure in Pompe disease: treatment with noninvasive ventilation. Neurology 2005;64:1465-1467.
31. Pellegrini N, Laforet P, Orlikowski D, Pellegrini M, Caillaud C, Eymard B, Raphael JC, Lofaso F. Respiratory insufficiency and limb muscle weakness in adults with Pompe's disease. Eur Respir J 2005;26:1024-1031.
32. van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, Smit GP, Poll-The BT, Bakker HD, Loonen MC, de Klerk JB, Reuser AJ, et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics 2003;112:332-340.
33. Haley SM, Fragala MA, Skrinar AM. Pompe disease and physical disability. Dev Med Child Neurol 2003;45:618-623.
34. Marsden D. Infantile onset Pompe disease: a report of physician narratives from an epidemiologic study. Genet Med 2005;7:147-150.
35. Hagemans ML, Winkel LP, Hop WC, Reuser AJ, Van Doorn PA, Van der Ploeg AT. Disease severity in children and adults with Pompe disease related to age and disease duration. Neurology 2005;64:2139-2141.
36. Margolis ML, Howlett P, Goldberg R, Eftychiadis A, Levine S. Obstructive sleep apnea syndrome in acid maltase deficiency. Chest 1994;105:947-949.
37. Kansagra S, Austin S, Dearmey S, Kishnani PS, Kravitz RM. Polysomnographic findings in infantile Pompe disease. Am J Med Genet A 2013;161A:3196-3200.
38. Beck M. Alglucosidase alfa: long term use in the treatment of patients with Pompe disease. Ther Clin Risk Manag 2009;5:767-772.
39. Schneider I, Hanisch F, Muller T, Schmidt B, Zierz S. Respiratory function in late-onset Pompe disease patients receiving long-term enzyme replacement therapy for more than 48 months. Wien Med Wochenschr 2013;163:40-44.
40. Byrne BJ, Kishnani PS, Case LE, Merlini L, Muller-Felber W, Prasad S, der Ploeg A. Pompe disease: design, methodology, and early findings from the Pompe Registry. Mol Genet Metab 2011;103:1-11.
41. Toscano A, Schoser B. Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review. J Neurol 2013;260:951-959.
42. Van den Hout JM, Kamphoven JH, Winkel LP, Arts WF, De Klerk JB, Loonen MC, Vulto AG, Cromme-Dijkhuis A, Weisglas-Kuperus N, Hop W, et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 2004;113:e448-e457.
43. Orlikowski D, Pellegrini N, Prigent H, Laforet P, Carlier R, Carlier P, Eymard B, Lofaso F, Annane D. Recombinant human acid alphaglucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease. Neuromuscul Disord 2011;21:477-482.
44. Kikuchi T, Yang HW, Pennybacker M, Ichihara N, Mizutani M, Van Hove JL, Chen YT. Clinical and metabolic correction of Pompe disease by enzyme therapy in acid maltase-deficient quail. J Clin Invest 1998;101:827-833.
45. Raben N, Danon M, Gilbert AL, Dwivedi S, Collins B, Thurberg BL, Mattaliano RJ, Nagaraju K, Plotz PH. Enzyme replacement therapy in the mouse model of Pompe disease. Mol Genet Metab 2003;80:159-169.
46. Arai AC, Kessler M. Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior. Curr Drug Targets 2007;8:583-602.
47. Porrino LJ, Daunais JB, Rogers GA, Hampson RE, Deadwyler SA. Facilitation of task performance and removal of the effects of sleep deprivation by an ampakine (CX717) in nonhuman primates. PLoS Biol 2005;3:e299.
48. Boyle J, Stanley N, James LM, Wright N, Johnsen S, Arbon EL, Dijk DJ. Acute sleep deprivation: the effects of the AMPAKINE compound CX717 on human cognitive performance, alertness and recovery sleep. J Psychopharmacol 2012;26:1047-1057.
49. Henneman E, Somjen G, Carpenter DO. Excitability and inhibitability of motoneurons of different sizes. J Neurophysiol 1965;28:599-620.
50. Eldridge FL. Relationship between phrenic nerve activity and ventilation. Am J Physiol 1971;221:535-543.
51. Grassino A, Sorli J, Lorange G, Milic-Emili J. Respiratory drive and timing in chronic obstructive pumonary disease. Chest 1978;73:290-293.
52. Nichols NL, Gowing G, Satriotomo I, Nashold LJ, Dale EA, Suzuki M, Avalos P, Mulcrone PL, McHugh J, Svendsen CN, et al. Intermittent hypoxia and stem cell implants preserve breathing capacity in a rodent model of amyotrophic lateral sclerosis. Am J Respir Crit Care Med 2013;187:535-542.
53. Nichols NL, Johnson RA, Satriotomo I, Mitchell GS. Neither serotonin nor adenosine-dependent mechanisms preserve ventilatory capacity in ALS rats. Respir Physiol Neurobiol 2014;197:19-28.
54. Burrow TA, Bailey LA, Kinnett DG, Hopkin RJ. Acute progression of neuromuscular findings in infantile Pompe disease. Pediatr Neurol 2010;42:455-458.
55. Smith BK, Collins S, Conlon T, Mah C, Lawson LA, Martin D, Fuller DD, Cleaver B, Clement N, Phillips D, et al. Phase I/II trial of AAV1-GAA gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes. Hum Gene Ther 2013;24:630-640.